Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: 20 mg + rimonabant weight + rimonabant  Related to the article below (Last Update: 5/5/2008)

ADAGIO-LIPIDS: Rimonabant reduces visceral fat and improves lipid ...
TheHeart.Org, NY - May 1, 2008
In total, 370 patients were randomized to rimonabant 20 mg and another 370 patients to placebo. Both groups reduced caloric intake 600 kcal after ...
Rimonabant Improves Atherogenic Lipid Profile, Reduces Visceral ...
DG News - May 1, 2008
After a 1-week screening period, 799 patients were randomised to rimonabant 20 mg daily (n = 404) or placebo (n = 395) for 1 year. ...
Pill Weight Loss
PR-USA.net (press release), Bulgaria - Apr 16, 2008
See below for more information about Generic Acomplia Rimonabant 20 Mg. We also offer Branded Acomplia Rimonabant which is manufactured by Sanofi-Aventis. ...
Source: Google News

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia -
JP Despres, A Golay, L Sjostrom? - New England Journal of Medicine, 2005 - content.nejm.org
... As compared with placebo, rimonabant at a dose of 20 mg was associated with a
significant (P<0.001) mean weight loss (repeated-measures method, ?6.7?0.5 kg ...

… Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk …
FX Pi-Sunyer, LJ Aronne, HM Heshmati, J Devin, J … - JAMA, 2006 - Mass Med Soc
... Among study completers (just over half of initial enrollees), 20-mg rimonabant was
associated with significant improvements in body weight and metabolic ...

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk … -
LF Van Gaal, AM Rissanen, AJ Scheen, O Ziegler, S … - The Lancet, 2005 - Elsevier
... 6?4]). Significantly more patients treated with rimonabant 20 mg than placebo achieved
weight loss of 5% or greater (p<0?001) and 10% or greater (p<0?001). ...

Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors … -
FX Pi-Sunyer, LJ Aronne, HM Heshmati, J Devin, J … - JAMA, 2006 - Am Med Assoc
... group to the placebo group during year 2 experienced weight regain while those who
continued to receive 20 mg of rimonabant maintained their weight loss and ...

Rimonabant for overweight or obesity.
C Curioni, C Andre - ncbi.nlm.nih.gov
... Compared with placebo, rimonabant 20 mg produced a 4.9 kg greater reduction
in body weight in trials with one-year results. Improvements ...

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a …
AJ Scheen, N Finer, P Hollander, MD Jensen, LF Van … - The Lancet, 2006 - Elsevier
... The main finding of the RIO-Diabetes trial is that 20 mg/day rimonabant for 1 year
significantly reduced weight, waist circumference, and HbA 1c levels and ...

Rimonabant-A Selective CB1 Antagonist -
ST Boyd, BA Fremming - The Annals of Pharmacotherapy, 2005 - Harvey Whitney Books
... Patients who were overweight or obese lost weight when treated with rimonabant
20 mg/day; however, normal-weight patients did not. ...

Rimonabant: A Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk … -
EV Gelfand, CP Cannon - Journal of the American College of Cardiology, 2006 - Am Coll Cardio Found
... In four large trials, after one year of treatment, rimonabant 20 mg led to greater
weight loss and reduction in waist circumference compared with placebo. ...

Drug treatments for obesity: orlistat, sibutramine, and rimonabant
RS Padwal, SR Majumdar - The Lancet, 2007 - Elsevier
... North America, rimonabant-treated patients re-randomised to placebo in year 2 regained
weight, whereas those who continued to receive the 20 mg dose maintained ...

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials -
R Christensen, PK Kristensen, EM Bartels, H … - The Lancet, 2007 - Elsevier
... After a weight maintenance diet for 4 weeks, patients who were compliant to ... randomly
assigned to placebo, rimonabant 5 mg per day, or rimonabant 20 mg per day ...

Source: Google Scholar

Quitting And Keeping The Weight Off With Rimonabant 20 Mg
Using selective cannabinoid 1 (CB1) receptor antagonists such as rimonabant at a dose of 20 mg per day can help people quit smoking, can help them to remain abstinent, and can help prevent the weight gain that so often accompanies attempts at stopping smoking. The lower dose of 5mg, however, was not shown to be effective, according to a Cochrane Systematic Review.
Smoking tobacco sends nicotine into the blood stream, and this chemical disrupts the endocannabinoid system, part of the hormonal control mechanism in the brain that controls energy balance and food intake. Over time the body alters the nature of its energy mechanism to compensate for this effect. Stopping smoking removes the nicotine and once again disturbs the mechanism, adding to the withdrawal symptoms and leaving a person prone to put on weight.

One potential way of preventing this is to take a drug that blocks the receptor that is involved in nicotine's action in the brain -- the cannabinoid 1 receptor. These CB1 receptor antagonists could therefore form part of a therapeutic programme aimed at helping individuals quit smoking, although this drug has not yet been approved as a smoking cessation treatment in the USA or in Europe.

To see whether there was evidence that these receptor antagonists work two Cochrane Researchers, Kate Cahill who works at the Department of Primary Care in the University of Oxford and Michael Ussher who works at St George's, University of London, searched the published and unpublished literature for relevant research projects. They found three trials that involved a total of 1567 smokers and 1661 people who had recently quit smoking. Analysing the data showed that the effect of the drug depended on the dose used:

Quitting with 20mg rimonabant:

People given 20 mg rimonabant increased by 50% their odds of remaining abstinent compared with those on placebo. Smokers who had quit while using 20mg rimonabant increased by 50% their odds of staying abstinent if they continued taking either 5mg or 20mg rimonabant, compared with those who moved to placebo treatment after quitting.
Quitting with 5mg rimonabant:

People who wanted to quit appeared to gain no benefit from 5 mg rimonabant treatment. Furthermore the people who did manage to quit using this lower dose were equally likely to remain abstinent whether they continued with rimonabant treatment or moved to a placebo.

Weight gain:

Weight gain appeared to be significantly lower in people who quit while using 20 mg rimonabant than those taking either 5 mg rimonabant or placebo. The differences in weight between the groups appeared to be maintained through longest follow-up. This beneficial effect was more evident in overweight or obese smokers than in those of normal weight.

"From the preliminary data that we found it appears that 20mg rimonabant may significantly increase a person's likelihood of quitting and may also reduce the amount of weight that they gain," says Cahill.

Source: Jennifer Beal
John Wiley & Sons, Inc.
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.